Binding of monosodium urate crystals with idiotype protein efficiently promote dendritic cells to induce cytotoxic T cells

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2268-2273

  Sakamaki, Ippei ^a,b   Inai, Kunihiro ^b   Tsutani, Yoko ^a   Ueda, Takanori ^b   Tsutani, Hiroshi ^a  

^a National Hospital Organization Awara Hospital   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; HLA A2 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; URATE;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; IN VITRO STUDY; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TARGET CELL; TUMOR IMMUNITY;

BINDING SITES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; T-LYMPHOCYTES, CYTOTOXIC; URIC ACID;

EID: 55449134184     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00939.x     Document Type: Article

References (26)

1. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-8.
2. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26.
3. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-19.
4. Abdalla AO, Hansson L, Eriksson I et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems. Haematologica 2007; 92: 110-14.
5. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Haematol 2000; 108: 805-16.
6. Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-8.
7. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002; 100: 230-7.
8. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
9. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-62.
10. Terkeltaub R, Tenner AJ, Kozin F, Ginsberg MH. Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. Arthritis Rheum 1983; 26: 775-83.
11. Kozin F, McCarty DJ. Molecular orientation of immunoglobulin G adsorbed to microcrystalline monosodium urate monohydrate. J Laboratory Clin Med 1980; 95: 49-58.
12. McCarty DJ Jr, Faires JS. A comparison of the duration of local anti-inflammatory effect of several adrenocorticosteroid esters - a bioassay technique. Curr Ther Res Clin Exp 1963; 5: 284-90.
13. Marten A, Renoth S, von Lilienfeld-Toal M et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001; 86: 1029-37.
14. Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435-42.
15. +) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999; 73: 5402-10.
16. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002; 100: 961-5.
17. Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106: 1278-85.
18. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 1998; 161: 1313-19.
19. Mehlhop E, Villamide LA, Frank I et al. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J Immunol Meth 2002; 260: 219-34.
20. Sato M, Takayama T, Tanaka H et al. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E (2). Cancer Sci 2003; 94: 1091-8.
21. Okamoto M, Furuichi S, Nishioka Y et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 2004; 64: 5461-70.
22. Shi Y, Galusha SA, Rock KL. Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 2006; 176: 3905-8.
23. Ma XJ, Tian DY, Xu D et al. Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice. World J Gastroenterol 2007; 13: 1060-6.
24. Behrens MD, Wagner WM, Krco CJ et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008; 111: 1472-9.
25. Kuehl WM. Modeling multiple myeloma by AID-dependent conditional activation of MYC. Cancer Cell 2008; 13: 85-7.
26. Chesi M, Robbiani DF, Sebag M et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-80.